Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clavulanate Potassium

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
28
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Clavulanate Potassium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Infection
  • Infectious otitis media
  • Otitis media
  • Pneumonia
  • Respiratory tract infectious disorder
  • Sinusitis
  • Soft Tissue Infections
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Combinations of penicillins, incl. beta-lactamase inhibitors
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CR02

Repurposing investigation

Clavulanate Potassium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA4.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli74.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae73.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 8 lab records
  • E. coli: measured active in 9 of 16 lab records
  • K. pneumoniae: measured active in 4 of 4 lab records
Open Clavulanate Potassium in ChEMBL Registered studies below
Show the 28 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clavulanate Potassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients

    NCT00354965 · start 2006-01-19

    Registered record
    Registry ID
    NCT00354965
    Conditions
    Infections, Respiratory Tract
    Interventions
    amoxicillin/clavulanate potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-01-19
    Completion
    2007-04-02
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Respiratory Tract
    Interventionamoxicillin/clavulanate potassium
    PhasePhase 1
    Registry statusCompleted

  • Guidelines for Acute Sinusitis

    NCT00132275 · start 2003-11

    Registered record
    Registry ID
    NCT00132275
    Conditions
    Sinusitis
    Interventions
    Amoxicillin potassium clavulanate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-11
    Completion
    2006-08
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSinusitis
    InterventionAmoxicillin potassium clavulanate
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions

    NCT00778661 · start 2002-10

    Registered record
    Registry ID
    NCT00778661
    Conditions
    Healthy
    Interventions
    amoxicillin 400mg + clovalunic acid 57.5mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-10
    Completion
    2002-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionamoxicillin 400mg + clovalunic acid 57.5mg tablets
    PhaseNot applicable
    Registry statusCompleted

  • Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment

    NCT01559753 · start 1998-01

    Registered record
    Registry ID
    NCT01559753
    Conditions
    Pneumonia Ventilator Associated
    Interventions
    Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; compare 8 to15 days of antibiotic treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1998-01
    Completion
    2002-11
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia Ventilator Associated
    InterventionAugmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; compare 8 to15 days of antibiotic treatment
    PhasePhase 4
    Registry statusCompleted

  • Acupuncture and Herbal Treatment of Chronic HIV Sinusitis

    NCT00002149

    Registered record
    Registry ID
    NCT00002149
    Conditions
    HIV Infections; Sinusitis
    Interventions
    Clavulanate potassium; Pseudoephedrine hydrochloride; Amoxicillin trihydrate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Sinusitis
    InterventionClavulanate potassium; Pseudoephedrine hydrochloride; Amoxicillin trihydrate
    PhaseNot applicable
    Registry statusCompleted